Sentry Investment Management LLC cut its holdings in shares of Zoetis Inc (NYSE:ZTS) by 50.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,662 shares of the company’s stock after selling 38,662 shares during the quarter. Sentry Investment Management LLC’s holdings in Zoetis were worth $2,785,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Scotia Capital Inc. grew its holdings in shares of Zoetis by 1.5% during the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock worth $601,000 after purchasing an additional 142 shares during the period. Dynamic Technology Lab Private Ltd boosted its holdings in Zoetis by 7.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after acquiring an additional 401 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Zoetis by 4.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after acquiring an additional 697 shares during the period. Sandy Spring Bank boosted its holdings in Zoetis by 2.3% during the 4th quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after acquiring an additional 708 shares during the period. Finally, Wendell David Associates Inc. boosted its holdings in Zoetis by 8.4% during the 4th quarter. Wendell David Associates Inc. now owns 10,300 shares of the company’s stock valued at $742,000 after acquiring an additional 800 shares during the period. Institutional investors and hedge funds own 93.72% of the company’s stock.
Zoetis Inc (NYSE:ZTS) opened at $73.19 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The stock has a market capitalization of $35,255.31, a PE ratio of 33.19, a PEG ratio of 1.60 and a beta of 1.06. Zoetis Inc has a 52 week low of $52.00 and a 52 week high of $80.13.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Thursday, January 18th. This is a boost from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is presently 26.32%.
A number of equities analysts recently commented on the company. Piper Jaffray Companies restated a “buy” rating and set a $86.00 target price on shares of Zoetis in a report on Thursday, January 18th. BMO Capital Markets set a $78.00 target price on Zoetis and gave the company a “hold” rating in a report on Monday, January 22nd. Jefferies Group restated a “buy” rating and set a $89.00 target price on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the company a “buy” rating in a report on Thursday, January 11th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $73.72.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/zoetis-inc-zts-shares-sold-by-sentry-investment-management-llc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.